An Adaptive Phase 2/3 study of Clofazimine inhalation suspension for treatment of lung disease

Status: Planning

Phase of Trial: Phase II/III

Latest Information Update: 29 Feb 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

27 Feb 2024 According to a MannKind Corporation media release, will host a conference call and presentation webcast to discuss results today at 5:00 p.m. Eastern Time.
27 Feb 2024 According to a MannKind Corporation media release, Phase 3 development program aligned with the FDA- IND expected to be filed in 1Q 2024, up to 100 global sites, first patient expected to enroll in 2Q 2024.
23 Feb 2023 According to a MannKind Corporation media release, this study is expected to begin in the second half of 2023.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com